SK Biopharmaceuticals Entered into a License Agreement with Eurofarma to Develop and Commercialize Cenobamate for Epilepsy in Latin America
Shots:
- Eurofarma gets exclusive rights to develop & commercialize cenobamate in Latin America. In exchange, SK will receive $15M up front & will be eligible to receive ~$47M milestones along with royalties
- The agreement strengthens the dedication to developing therapies for CNS disorders & offers solutions for epilepsy sufferers globally. The agreement also broadens SK Biopharmaceutical’s footprint globally to provide cenobamate to the patient community
- Enobamate has been approved in the US & EU for partial-onset seizures in adults & is also available under the brand name Xcopri. The four continents of North America, EU, Asia, and Latin America will now be served by SK
Ref: PRNewswire | Image: SK Biopharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
